Due to the strong evidence regarding the correlation between MUC1 and drug resistance in malignant tumors, MUC1 became the promising target of new therapeutic strategies based on the inhibition of its expression or functions, which could improve PDAC patient responses to conventional therapies. Here, MUC1 is linked to cancer.